For media inquiries, please contact David Seldin at Brunswick Group at +1 (202) 393-7337 or via email at Samumed@brunswickgroup.com.

2017

2016

Date Title
11/16/2016 Samumed Presents Data For Potential Topical Treatment for Psoriasis
11/15/2016 Samumed's Wnt Pathway Modulator SM04690 Shows Potential as a Disease Modifying Treatment for Osteoarthrits (OA) of the Knee
11/15/2016 Samumed Presents Data for a Small Molecule Modulator of the Wnt Pathway as a Potential Treatment for Degenerative Disc Disease
11/14/2016 Samumed Presents Data for a Small Molecule Modulator of Wnt Pathway as a potential topical treatment for Chronic Tendinopathy
11/14/2016 Samumed, LLC Presents Data for Small Molecule Modulator of Wnt Pathway as a Potential Topical Treatment for Scleroderma
11/01/2016 Samumed Selected for Seven Presentations in Five Therapeutic Areas at American College of Rheumatology 2016 Annual Meeting
10/25/2016 Samumed Successfully Completes a Phase II Androgenetic Alopecia (“AGA”) Biopsy Trial Studying Regeneration of Hair Follicles
10/13/2016 Samumed CEO to Present at Forbes Healthcare Summit
09/17/2016 Samumed’s CEO presents their regenerative medicine platform at the Royal Society of Medicine’s 13th Medical Innovations Summit
05/05/2016 CNBC Interview with Samumed's CEO
04/13/2016 Forbes.com: Cure Baldness? Heal Arthritis? Erase Wrinkles? An Unknown Billionaire's Quest To Reverse Aging
04/13/2016 Forbes.com: The Forbes Global Game Changers List: Bezos, Zuckerberg And More Business Leaders Transforming The World
03/07/2016 Samumed presents at the annual meeting of the American Academy of Dermatology (AAD) Safety and Efficacy results from its Phase 2 androgenetic alopecia (AGA) trial

2015